What question did this study set out to answer?

This study aims to characterize the clinical features and survival outcomes of patients with grade 1 myxoid liposarcoma.

March 12, 2026Open Access

133P Clinicopathologic and molecular predictors of early relapse in high-risk gastrointestinal stromal tumors (GIST)

JSJoel Jia Yi SoonChangi General Hospital JLJ. Jack LeeThe University of Texas MD Anderson Cancer Center HTHY TayNational Cancer Centre Singapore

Key Points

This study aims to characterize the clinical features and survival outcomes of patients with grade 1 myxoid liposarcoma.
Retrospective analysis of patients with histologically confirmed grade 1 MLPS treated at Gustave Roussy.
Data collected from electronic medical records included demographics, tumor site, and disease stage.
Survival outcomes analyzed using the Kaplan-Meier method.
178 patients with grade 1 MLPS were included, with a median age of 43 years.
25.3% experienced local relapse and 23.6% developed metastatic disease during follow-up.
Median overall survival was not reached; estimated survival rates at 1, 5, and 10 years were 94.6%, 81.4%, and 69.0% respectively.

Abstract

Background: Myxoid liposarcoma (MLPS) is traditionally classified into low-and highgrade (HG) based on the round cell (RC) component, with >5% RC indicating HG disease.In parallel, the FNCLCC grading system, routinely applied to sarcomas, is also used in MLPS and may assign an alternative grading system.Although MLPS is considered an intermediate-grade malignancy, FNCLCC grade 1 MLPS represents a distinct subgroup with indolent behavior but a persistent risk of local and distant recurrence.However, long-term outcomes of this low-grade subset remain poorly defined.The aim of this study was to characterize the clinical features and survival outcomes of pts with grade 1 MLPS.Methods: This retrospective study included all pts with histologically confirmed grade 1 MLPS treated at Gustave Roussy between January 1990 and March 2024 from the institutional database.Clinical data, including demographics, primary tumor site, and disease stage, were collected from electronic medical records.Survival outcomes were estimated using the Kaplan-Meier method.Results: 178 pts with grade 1 MLPS were included, with a median age of 43 yrs and 62.9% were males.Median tumor size was 10 cm (3 cm; 30 cm).Four had metastatic disease (2.3%) with lung lesions in 3 pts.Most common tumor sites were in lower limbs (78.1%), most in hips (108 pts, 61.2%) and knees (17 pts, 9.6%).They rarely occurred in upper limbs (3pts, 1.7%) or trunk (17 patients, 9.6%).Most pts had surgery (92.7%), with 50% receiving RT (21.9% in neoadjuvant (NAT).Chemotherapy was given to 25 pts (14.6% with NAT in 11.2%), while isolated limb perfusion was done in 9 (5.1%).With a follow-up of 84 mo, 25.3% (43 pts) had local relapse and 23.6% (41 pts) developed metastatic disease.Median time to local and distant relpase were 26.74 mo and 40.42 mo.Median overall survival was not reached, while estimated survival at 1, 5, and 10 years were 94.6% (95% CI: 89.9-97.2),81.4% (95% CI: 74.0-86.9),and 69.0%(95% CI: 59.3-76.8). Conclusions:In this cohort, grade 1 MLPS demonstrated a generally favorable prognosis with 25.3% and 23.6% risk of local and distant relapse, respectively.Identifying prognostic factors within this indolent subtype may help refine treatment strategies in localized disease and guide the long-term surveillance of affected patients.

KI fragen

Bookmark

View Full Paper